Guardant Health (GH) Stock Overview
A precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
GH Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Guardant Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$103.10 |
| 52 Week High | US$120.74 |
| 52 Week Low | US$34.88 |
| Beta | 1.65 |
| 1 Month Change | -10.15% |
| 3 Month Change | -7.33% |
| 1 Year Change | 140.49% |
| 3 Year Change | 256.99% |
| 5 Year Change | -29.95% |
| Change since IPO | 220.19% |
Recent News & Updates
Recent updates
Guardant Health: Look For Explosive Revenue Growth Ahead
Jan 26Earnings Update: Guardant Health, Inc. (NASDAQ:GH) Just Reported And Analysts Are Boosting Their Estimates
Nov 02
Guardant Health, Inc. (NASDAQ:GH) Stocks Shoot Up 48% But Its P/S Still Looks Reasonable
Oct 31Guardant Health, Inc. (NASDAQ:GH) Looks Just Right With A 26% Price Jump
Jun 19
Medicare Coverage Of Reveal And Shield's FDA Approval Will Expand Market Reach
Achieving ASP goals and expanding Medicare coverage will drive revenue growth through higher pricing and increased test volumes.Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
Feb 13Guardant Health: Remains Risky Despite SHIELD's Early Success
Jan 21Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Shareholder Returns
| GH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -1.7% | -0.8% | 1.0% |
| 1Y | 140.5% | -14.3% | 14.6% |
Return vs Industry: GH exceeded the US Healthcare industry which returned -14.3% over the past year.
Return vs Market: GH exceeded the US Market which returned 14.4% over the past year.
Price Volatility
| GH volatility | |
|---|---|
| GH Average Weekly Movement | 6.3% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2,010 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults.
Guardant Health, Inc. Fundamentals Summary
| GH fundamental statistics | |
|---|---|
| Market cap | US$13.47b |
| Earnings (TTM) | -US$416.28m |
| Revenue (TTM) | US$982.02m |
Is GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GH income statement (TTM) | |
|---|---|
| Revenue | US$982.02m |
| Cost of Revenue | US$349.01m |
| Gross Profit | US$633.01m |
| Other Expenses | US$1.05b |
| Earnings | -US$416.28m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.19 |
| Gross Margin | 64.46% |
| Net Profit Margin | -42.39% |
| Debt/Equity Ratio | -1,514.5% |
How did GH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 21:51 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guardant Health, Inc. is covered by 32 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |